Plexxikon Inc. (Plexxikon)

Oncology Corporate Profile

HQ Location

91 Bolivar Drive
Berkeley, CA 94710

Company Description

Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage programs in a number of therapeutic areas and disease indications. Plexxikon's platform enables the design of highly selective and targeted medicines, supporting the company's broader strategy to develop personalized medicines.

Website: http://www.plexxikon.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PLX3397CSF1 inhibitorTenosynovial giant cell tumor (TGCT)III
PLX3397 (eribulin)CSF1 inhibitorBreast cancerII
PLX3397 (+ radiation therapy and temozolomide)CSF1 inhibitorGlioblastoma Multiforme (GBM)II
PLX3397 (+ paclitaxel)CSF1 inhibitorNeoadjuvant Breast cancerII
PLX3397 (+ pembrolizumab)CSF1 inhibitorMelanomaI
PLX3397 (+ pembrolizumab)CSF1 inhibitorOvarian cancerI
PLX3397 (+ pembrolizumab)CSF1 inhibitorVarious cancer typesI
PLX7486CSF1 inhibitorPancreatic cancer
PLX9486CSF1 inhibitorGastrointestinal Stromal Tumors (GIST)Preclinical

View additional information on product candidates here »

Source: http://www.plexxikon.com

Recent News Headlines

There are no news items to display